JP2010523696A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523696A5
JP2010523696A5 JP2010503205A JP2010503205A JP2010523696A5 JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5 JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5
Authority
JP
Japan
Prior art keywords
methyl
dose
effective amount
carboplatin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/059905 external-priority patent/WO2008124822A1/en
Publication of JP2010523696A publication Critical patent/JP2010523696A/ja
Publication of JP2010523696A5 publication Critical patent/JP2010523696A5/ja
Pending legal-status Critical Current

Links

JP2010503205A 2007-04-10 2008-04-10 脳腫瘍を治療する方法 Pending JP2010523696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91097507P 2007-04-10 2007-04-10
PCT/US2008/059905 WO2008124822A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Publications (2)

Publication Number Publication Date
JP2010523696A JP2010523696A (ja) 2010-07-15
JP2010523696A5 true JP2010523696A5 (https=) 2011-07-14

Family

ID=39831435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503205A Pending JP2010523696A (ja) 2007-04-10 2008-04-10 脳腫瘍を治療する方法

Country Status (9)

Country Link
US (1) US20100129470A1 (https=)
EP (1) EP2144504A4 (https=)
JP (1) JP2010523696A (https=)
KR (1) KR20100016385A (https=)
CN (1) CN101742910A (https=)
AU (1) AU2008236993A1 (https=)
CA (1) CA2720982A1 (https=)
NZ (1) NZ580866A (https=)
WO (1) WO2008124822A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
CN102088854A (zh) * 2008-07-11 2011-06-08 美瑞德生物工程公司 作为细胞毒素剂的药物化合物及其使用方法
US20110224240A1 (en) * 2010-01-11 2011-09-15 Myrexis, Inc. Methods of treating cancer and related diseases
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
CN113842392A (zh) * 2013-06-05 2021-12-28 西特克斯公司 用于治疗癌症的细胞毒素剂
CN105288629B (zh) * 2014-05-28 2021-02-19 北京大学 具有药效叠加作用及毒性分散效应的组合药物
GB2553716B (en) * 2015-04-17 2020-06-17 Univ Holy Ghost Duquesne Pyrrolopyrimidines as antitumor agents
WO2019211829A1 (en) * 2018-05-02 2019-11-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating glioblastoma
CA3108044A1 (en) * 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
CN116143693B (zh) * 2020-06-24 2026-04-10 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139641A0 (en) * 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
US7001926B2 (en) * 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CN1589151A (zh) * 2001-09-21 2005-03-02 图兰恩教育基金管理人 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
CA2536140A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
WO2006074187A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Method of treating brain cancer
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
NZ580868A (en) * 2007-04-10 2011-07-29 Myriad Pharmaceuticals Inc Dosages and methods for the treatment of cancer
WO2009023876A1 (en) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Method of treating non-small cell lung cancer

Similar Documents

Publication Publication Date Title
JP2010523696A5 (https=)
JP2013503174A5 (https=)
Zhang et al. Smart Cu (II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma
US11224599B2 (en) Therapeutic agents and methods
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
JP2008535902A5 (https=)
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
CR7693A (es) Terapia de combinacion para enfermedades hiperproliferativas
RU2012111235A (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
TW201107327A (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
PH12012500504A1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
WO2009012096A3 (en) Improved therapeutic methods and compositions comprising chroman ring compounds
WO2009120697A4 (en) Method and compositions for treatment of cancer
US11702443B2 (en) Therapeutic agents and methods
JP2015514756A5 (https=)
JP2009506054A5 (https=)
JPWO2015115310A1 (ja) がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
JP2013520499A5 (https=)
Iqubal et al. A technical note on emerging combination approach involved in the onconanotherapeutics
HUP0301247A2 (hu) Antitumor terápia disztamicin származékokkal